Otros idiomas Marinus Pharmaceuticals, Inc. Mexican S.E.

Acciones

MRNS *

US56854Q2003

Precio de cierre Mexican S.E. Otros sitios de cotización 00:00:00 15/04/2024			Varia. Cinco días.	Varia. 1 de enero.
124 ^MXN	-2,36 %		-.--%	-2,36 %

17/05	Actualización del sector: Los valores del sector sanitario, mixtos a última hora de la tarde	MT
17/05	Actualización del sector: Atención sanitaria	MT

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Marinus Pharmaceuticals Announces Key Business Updates for Tuberous Sclerosis Complex Program	20/05
Sector Update: Health Care Stocks Mixed Late Afternoon	17/05
Sector Update: Health Care	17/05
Marinus Completes Enrollment in Tuberous Sclerosis Complex Trial; Gets New Patent	17/05
Marinus Pharmaceuticals, Inc. Announces Key Business Updates for Tuberous Sclerosis Complex Program	17/05
Marinus Pharmaceuticals Announces Key Business Updates for Tuberous Sclerosis Complex Program	17/05
Actinium Pharmaceuticals (ATNM) Poised for Breakout as Analysts Project Significant Upside	09/05
Earnings Flash (MRNS) MARINUS PHARMACEUTICALS Reports Q1 Revenue $7.7M, vs. Street Est of $9.1M	08/05
Marinus Pharmaceuticals: Q1 Earnings Snapshot	08/05
Marinus Pharmaceuticals : Corporate Overview Slide Deck	08/05
Marinus Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	08/05
Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results	08/05
Marinus Pharmaceuticals, Inc. Increases Earnings Guidance for Full Year 2024	08/05
Marinus Pharmaceuticals to Present at the RBC Capital Markets 2024 Global Healthcare Conference	02/05
Marinus Pharmaceuticals to Provide Business Update and Report First Quarter 2024 Financial Results on May 8, 2024	01/05
North American Morning Briefing : Powell Comments, -2-	16/04
Sector Update: Health Care Stocks Softer Late Afternoon	15/04
Marinus Pharmaceuticals Shares Fall After Phase 3 Trial Interim Analysis of Ganaxolone	15/04
Marinus Pharmaceuticals Provides Update on the Phase 3 RAISE Trial and Reports Preliminary First Quarter 2024 Financial Results	15/04
Marinus Pharmaceuticals, Inc. Provides Update on the Phase 3 RAISE Trial	15/04

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Marinus Pharmaceuticals, Inc. Mexican S.E.

Acciones

MRNS *

US56854Q2003

Otros idiomas

Filtros